Logo for I-Mab

I-Mab Investor Relations Material

Latest events

Logo for I-Mab

H1 2024

I-Mab
Logo for I-Mab

H1 2024

28 Aug, 2024
Logo for I-Mab

Corporate Presentation

28 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from I-Mab

Access all reports
I-Mab is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of innovative biologics, particularly in the fields of immuno-oncology and immuno-inflammation. The company has a diverse pipeline, including several antibody-based therapies aimed at treating various forms of cancer. These include drugs in different phases of clinical trials, such as Uliledlimab for solid tumors and Lemzoparlimab for hematologic malignancies. The company is headquartered in Rockville, Maryland, and its shares are listed on the NASDAQ.